priors.science/reviews/targeted-therapy-breast-cancer

Targeted Therapy Breast Cancer

The current evidence on 8 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

8claims tracked
148primary papers reviewed
25 Oct 2026latest evidence review
6 Established · 2 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Olaparib or talazoparib in BRCA-mutant breast cancerBrca DnaEstablished91%19
Alpelisib in PIK3CA-mutant hormone receptor-positive metastatic breast cancerPi3k AktEstablished90%18
Capivasertib (AKT inhibitor) in hormone receptor-positive metastatic breast cancerPi3k AktEstablished90%17
CDK4/6 inhibitors plus endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancerCdk46Established88%24
Sacituzumab in third-line triple-negative breast cancerBrca DnaEstablished87%19
Abemaciclib adjuvant therapy in early breast cancerCdk46Established86%19
Pembrolizumab neoadjuvant therapy in triple-negative breast cancerIci BCLikely84%21
Pembrolizumab in PD-L1-positive metastatic triple-negative breast cancerIci BCLong-standingLikely82%17
Track Targeted Therapy Breast Cancer.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.